Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(16):1182-1183; doi:10.1093/jnci/djg027
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Coleman, C. N.
Right arrow Articles by Abrams, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coleman, C. N.
Right arrow Articles by Abrams, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

Inflammatory Breast Issue

C. Norman Coleman, Paul E. Wallner, Jeffrey S. Abrams

Affiliation of authors: C. N. Coleman, P. E. Wallner (Radiation Research Program), J. S. Abrams (Cancer Therapy Evaluation Program), Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

Correspondence to: C. Norman Coleman, MD, Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bldg. 10, Rm. B3B69, MSC 1002, Bethesda, MD 20892 (e-mail: ccoleman@mail.nih.gov).

The first 150 words of the full text of this article appear below.

When we were invited to write an editorial on the emerging use of partial-breast irradiation and accelerated partial-breast irradiation, the following questions arose:

  1. When should and do new treatment approaches enter routine clinical use?
  2. When are phase II and pilot data from single institutions ready for general applicability?
  3. Does the approval of a new device by the U.S. Food and Drug Administration imply it is ready for general clinical applicability?
  4. How can innovative approaches that require long-term data to judge equivalency be made available in the short and medium term?
  5. What are the roles of professional societies, research institutions, oversight bodies, and the National Cancer Institute in the introduction of new treatments?
  6. How might overly cautious interpretation of pilot data inappropriately delay implementation of novel and/or breakthrough treatments?
  7. How might overly enthusiastic interpretation of pilot data inappropriately promote implementation of novel treatments?
  8. How does one ensure proper quality assurance as . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. R. Harris
Radiation Therapy for Invasive Breast Cancer: Not Just for Local Control
J. Clin. Oncol., March 10, 2005; 23(8): 1607 - 1608.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Vinh-Hung and C. Verschraegen
Breast-Conserving Surgery With or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality
J Natl Cancer Inst, January 21, 2004; 96(2): 115 - 121.
[Abstract] [Full Text] [PDF]